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Background-—Literature studies suggested a lower prevalence of coronary artery disease (CAD) in bicuspid aortic valve (BAV) than
in tricuspid aortic valve (TAV) patients. However, this ﬁnding has been challenged. We performed a meta-analysis to assess
whether aortic valve morphology has a different association with CAD, concomitant coronary artery bypass grafting (CABG), and
postoperative mortality.
Methods and Results-—Detailed search was conducted according to the PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) guideline to identify all patients with BAV or TAV and presence of CAD, concomitant myocardial
surgical revascularization, and the postoperative mortality. Thirty-one studies on 3017 BAV and 4586 TAV patients undergoing
aortic valve surgery were included. BAV patients showed a lower prevalence of CAD (odds ratio [OR]: 0.33; 95% CI: 0.17, 0.65),
concomitant CABG (OR, 0.45; 95% CI: 0.35, 0.59), and postoperative mortality (OR, 0.62; 95% CI: 0.40, 0.97) than TAV. However,
BAV subjects were signiﬁcantly younger than TAV (mean difference: 7.29; 95% CI: 11.17, 3.41) were more frequently males
(OR, 1.61; 95% CI: 1.33, 1.94) and exhibited a lower prevalence of hypertension (OR, 0.58; 95% CI: 0.39, 0.87) and diabetes (OR,
0.71; 95% CI: 0.54, 0.93). Interestingly, a metaregression analysis showed that younger age and lower prevalence of diabetes were
associated with lower prevalence of CAD (Z value: 3.03; P=0.002 and Z value: 3.10; P=0.002, respectively) and CABG (Z value:
2.69; P=0.007 and Z value: 3.36; P=0.001, respectively) documented in BAV patients.
Conclusions-—Analysis of raw data suggested an association of aortic valve morphology with prevalence of CAD, concomitant
CABG, and postoperative mortality. Interestingly, the differences in age and diabetes have a profound impact on prevalence of CAD
between BAV and TAV. In conclusion, our meta-analysis suggests that the presence of CAD is independent of aortic valve
morphology. ( J Am Heart Assoc. 2016;5:e003200 doi: 10.1161/JAHA.116.003200)
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A ortic valve stenosis (AVS) is considered the mostprevalent form of valve disease.1,2 The number of
people affected by this progressive and debilitating pathology
will increase because of the aging population, causing an ever-
increasing public health burden.3 Traditionally, it was thought
that AVS was related to valve degeneration attributed to
aging, caused by several years of mechanical stress and
biological response to such injury. However, more recently,
several risks factors have been linked to the development of
AVS, including male sex, hypertension, hyperlipidemia, smok-
ing, advanced age, and congenital bicuspid valve morphol-
ogy.4,5 Overall, AVS pathogenesis is a multifactorial process
and seems to be related to coronary atherosclerosis. In detail,
an important link between AVS and early stages of coronary
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atherosclerotic plaque has been hypothesized,6–8 and a
multitude of studies have been published regarding the
associations between AVS, coronary artery disease (CAD),
and coronary artery bypass grafting (CABG).9–12 In addition, a
very recent study by Boudoulas et al.13 describes the
association between aortic stenosis and CABG focusing on
valve morphology and concluding that “the incidence of
coronary artery disease is extremely high in patients with
aortic stenosis and tricuspid aortic valve.” However, literature
data are not consistent about this issue, and data about such
an association have been challenged. In addition, the critical
review of available studies highlights that, in most cases, only
univariate unadjusted analyses were used, seldom taking into
account for potential confounders. Thus, the aim of this study
was to perform a meta-analysis of literature studies enrolling
patients undergoing aortic valve surgery to assess whether
aortic valve morphology (tri- or bicuspid) impacts on preva-
lence of CAD, concomitant CABG, and postoperative mortal-
ity. In addition, to assess the presence of potential
confounders, we evaluated the impact of distribution of major
clinical and demographic variables between patients with bi-
or tricuspid aortic valve.
Methods
A protocol for this review was prospectively developed,
detailing the speciﬁc objectives, criteria for study selection,
outcomes, and statistical methods.
Search Strategy
To identify all available studies pertaining to prevalence of
CAD, deﬁned by atherosclerosis of 1 or more arteries that
supply blood to the heart causing oxygen deﬁciency in the
myocardium, we included articles with anamnestic CAD also
when it was not speciﬁed whether it was anatomical CAD
(70% stenosis or greater in at least 1 major coronary artery) or
clinical CAD (previous acute myocardial infarction or percu-
taneous coronary intervention). A detailed search was
conducted according to PRISMA (Preferred Reporting Items
for Systematic reviews and Meta-Analyses) guidelines14 to
identify all concomitant myocardial surgical revascularization
(CABG) and postoperative mortality in patients with bicuspid
aortic valve (BAV) and tricuspid aortic valve (TAV) undergoing
aortic valve surgery. A systematic search was performed in
the electronic databases (PubMed, Web of Science, Scopus,
and EMBASE), using the following search terms in all possible
combinations: tricuspid aortic valve; bicuspid aortic valve;
coronary artery disease; coronary artery bypass; myocardial
infarction; mortality; and death. The last search was
performed in November 2015. The search strategy was
developed without any language or publication year restric-
tion. In addition, the reference lists of all retrieved articles
were manually reviewed. In case of missing data, the authors
were contacted by e-mail to try to retrieve original data. Two
independent authors (P.P. and M.N.D.D.M.) analyzed each
article and performed the data extraction independently. In
case of disagreement, a third investigator was consulted
(L.C.). Discrepancies were resolved by consensus. Selection
results have been reported according to the PRISMA ﬂow
chart (Figure 1).
Data Extraction and Quality Assessment
According to the prespeciﬁed protocol, all studies evaluating
prevalence of CAD or use of CABG or postoperative mortality
in patients with BAV and in those with TAV undergoing aortic
valve replacement were included in the analysis. Case
reports, reviews, animal studies, and studies on natural
history of patients with aortic valve disease (not undergoing
surgery) were excluded. In each study, data regarding
sample size, major clinical and demographic variables,
number of patients with CAD, and number of those
undergoing CABG and those dying postoperatively were
extracted. Formal quality score adjudication was not used,
because previous investigations failed to demonstrate its
usefulness.15
Statistical Analysis and Risk of Bias Assessment
Statistical analysis was carried out using Comprehensive
Meta-analysis (version 2 [2005]; Biostat, Englewood, NJ).
Differences among BAV and TAV subjects were expressed as
mean difference (MD) with pertinent 95% CIs for continuous
variables, and as odds ratio (OR) with pertinent 95% CI for
dichotomous variables. Overall effect was tested using Z
scores, and signiﬁcance was set at P<0.05. Statistical
heterogeneity among studies was assessed with the chi-
square Cochran’s Q test and with the I2 statistic, which
measures the inconsistency across study results and
describes the proportion of total variation in study esti-
mates, that is, attributed to heterogeneity rather than
sampling error. In detail, I2 values of 0% indicate no
heterogeneity, 25% low, 25% to 50% moderate, and 50%
high heterogeneity.16
Publication bias was assessed by the Egger test and
represented graphically by funnel plots of the standard
difference in means versus SE. Visual inspection of funnel
plot asymmetry was performed to address for possible
small-study effect, as well as the Egger test to address
publication bias, over and above any subjective evaluation.
P<0.10 was considered statistically signiﬁcant.17 In order to
be as conservative as possible, the random-effect method
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was used to take into account the variability among included
studies.
Metaregression Analyses
We hypothesized that differences in prevalence of CAD, use of
CABG, or postoperative mortality between BAV and TAV
patients may be affected by differences in clinical and
demographic characteristics of patients included in different
studies (mean age, sex, body mass index [BMI], hypertension,
diabetes mellitus, hyperlipidemia, and smoking habit). To
assess the possible effect of such variables in explaining the
different results observed across studies, we planned to
perform metaregression analyses after implementing a
regression model with prevalence of CAD, use of CABG, or
postoperative mortality between BAV and TAV patients as
dependent variables (y) and the variables mentioned above as
independent variables (x).
Results
After excluding duplicate results, the search retrieved 282
articles. Of these studies, 232 were excluded because they
were off the topic after scanning the title and/or the abstract
and 19 because they were reviews/comments/case reports
or they lacked data of interest.
Thus, 31 articles (3017 BAV patients and 4586 TAV patients)
were included in the ﬁnal analysis (Figure 1). In detail, 15 studies
with data on prevalence of CAD (1163 BAV and 2234 TAV
patients), 16 reporting on use of CABG (1782 BAV and 1886 TAV
patients), and 16 on postoperative mortality rate (1067 BAV and
2399 TAV patients) were included.
Figure 1. PRISMA ﬂow diagram. BAV indicates bicuspid aortic valve; CT, computed tomography.
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Table 1. Demographic and Clinical Data of BAV and TAV
Author (Year) Reported Outcomes
Observation
Time Subjects Age, y Males Hypertension Hyperlipidemia Diabetes BMI Smoking
Abdulkareem
201318
CABG BAV 192 58 71.3
TAV 203 65 62.5
Ali 201019 CABG, mortality 7 years BAV 90 63 78.9 31.1 12.2 5.6
TAV 125 70 58.4 32.0 16.8 11.2
Asano 201220 CABG, mortality 5 years BAV 86 46.3
TAV 58 70
Badiu 201021 CAD, CABG,
mortality
5 years BAV 11 37 100.0 45.5 9.1
TAV 91 48 63.7 69.2 36.3 4.4
Boudoulas 201513 CABG BAV 95 62 71.6 70 61 31 53
TAV 175 71 55.4 87 60 47 48
Branchetti 201422 CAD BAV 74 55.5 64.9 31.1 27.0 5.4 43.2
TAV 61 64.4 70.5 42.6 42.6 13.1 19.7
Costopoulos
201423
Mortality 1 year BAV 21 76.7 57.1 66.7 28.6 26.6
TAV 447 79.8 47.4 77.2 30.2 26.1
Davies 199624 CABG BAV 296
TAV 125
Delius 199825 Mortality 10 years BAV 16
TAV 31
Eleid 201326 CAD, CABG BAV 47 58 76.6 68.1 48.9 8.5 23.4
TAV 53 66 75.5 86.8 49.1 11.3 13.2
Etz 201527 CAD, mortality Inhospital BAV 32 46.7 71.9 46.9 15.6
TAV 347 61.6 63.7 72.0 9.2 10.7
Girdauskas 201428 Mortality 10 years BAV 153 54 73.2 48.4 11.1 35.9
TAV 172 64 47.7 57.0 15.7 40.1
Holubec 201429 CAD, CABG,
mortality
2 years BAV 60 45* 81.7 45.0
TAV 40 59* 67.5 75.0
Hwang 201130 CAD, mortality 10 years BAV 45 59.6 60.0 44.4 2.2 6.7 26.7
TAV 43 58.3 48.8 23.3 2.3 9.3 9.3
Jackson 20149 CAD BAV 292 61.1 73.6 51.0 11.3
TAV 355 717 69.9 74.6 14.9
Kochman 201431 CAD, mortality 1 year BAV 28 77.6 46.4 60.7 39.3
TAV 84 79.1 47.6 65.5 34.5
Kvitting 201332 CABG BAV 63 43 79.4 36.5 4.8 26
TAV 170 36 67.6 25.9 2.4 24
Liu 201533 CAD, mortality 30 days BAV 15 75.4 60.0 33.3 23.6
TAV 25 75.8 68.0 56.0 12.0 21.7
Mosalanezhad
201434
CABG, mortality 8 years BAV 30 42 93.3
TAV 20 59 75.0
Continued
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Study Characteristics
Major characteristics of the 31 studies included in the meta-
analysis are shown in Table 1.
The number of patients varied from 23 to 647, mean age
from 36 to 79.8 years, and prevalence of male sex from
47.4% to 100%. Presence of hypertension was reported by
23.3% to 87.0% of patients, smoking habit by 9.3% to 53.0%,
diabetes mellitus by 2.4% to 47.0%, and hyperlipidemia by
2.2% to 78.5%. Mean BMI varied from 21.7 to 30.1 kg/m2.
Length of follow-up for mortality assessment ranged from in-
hospital stay period to 13 years with a median of 5 years.
Coronary Artery Disease
Fifteen studies,* for a total of 1163 BAV and 2234 TAV
patients, showed that CAD was reported by 13.5% of BAV and
30.3% of TAV patients (OR, 0.33; 95% CI: 0.17, 0.65; P=0.001;
Figure 2). Heterogeneity among studies was signiﬁcant
(I2=86%; P<0.001), and it was not reduced by the exclusion
of one study at a time. In addition, after excluding 2 studies by
Kochman et al.31 and Liu et al.,33 including patients under-
going transcatheter aortic valve implantation (TAVI), the
results were entirely conﬁrmed (OR, 0.31; 95% CI: 0.14,
0.66; P=0.002; I2=88%; P<0.001).
Concomitant CABG
Sixteen studies,** reporting on 1782 BAV and 1886 TAV
patients, showed that the number of patients undergoing
concomitant CABG was signiﬁcantly lower between BAV than
TAV patients (31.0% vs 45.7%; OR, 0.45; 95% CI: 0.35, 0.59;
P<0.001; Figure 3). Heterogeneity among studies was signif-
icant (I2=56%; P=0.003). However, after excluding the study by
Table 1. Continued
Author (Year) Reported Outcomes
Observation
Time Subjects Age, y Males Hypertension Hyperlipidemia Diabetes BMI Smoking
Nakamura 201435 CAD BAV 17 70 76.5 58.8 35.3 17.6 35.3
TAV 59 77 52.5 79.7 33.9 20.3 40.7
Philip 201510 CAD BAV 200 57 23.5 21.5 10.5
TAV 200 78 76.5 78.5 31.5
Roberts 200311 CABG BAV 232 64.7 72.0
TAV 267 74 51.3
Roberts 2007a36 CABG, mortality 5 years BAV 102
TAV 18
Roberts 2007b37 CABG, mortality 4 years BAV 187
TAV 235
Roberts 2007c38 CABG BAV 54
TAV 142
Roberts 2007d39 CABG, mortality 13 years BAV 180
TAV 107
Rylski 201412 CAD, mortality Inhospital BAV 41 55* 63.4 56.1 9.8
TAV 588 61* 64.1 81.1 9.2
Shim 201140 CAD BAV 50 52 78.0 40.0 20.0 12.0 24.7 32.0
TAV 50 52 78.0 50.0 28.0 8.0 25.2 42.0
Stephan 199741 CABG BAV 57 67 57.9
TAV 57 73 54.4
Warner 201342 CAD BAV 10 46.5 60.0 50.0 40.0 10.0 30.1 10.0
TAV 13 46.3 76.9 38.5 46.2 23.1
Yuan 201043 CAD BAV 241 56.1 77.2 30.7 24.1 10.8
TAV 225 62.8 64.0 41.8 24.9
*Data reported as median value. BAV indicates bicuspid aortic valve; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; TAV, tricuspid aortic valve.
*References 9, 10, 12, 21, 22, 26, 27, 29–31, 33, 35, 40, 42, 43. **References 11, 13, 18–21, 24, 26, 29, 32, 34, 36–39, 41.
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Asano et al.,20 all results were conﬁrmedwithout heterogeneity
(OR, 0.49; 95% CI: 0.39, 0.61; P<0.001; I2=37%; P=0.07).
Postoperative Mortality
The 16 studies*** evaluating postoperative mortality showed
a slightly signiﬁcant difference in rate of mortality between
BAV and TAV patients (16.2% vs 18.8%; OR, 0.62; 95% CI:
0.40, 0.97; P=0.04; I2=65%; P<0.001; Figure 4). Interestingly,
a metaregression analysis showed that the mortality rate was
independent by the length of the observation (Z value: 1.17;
P=0.240). In addition, we conducted a subanalysis removing
the 3 studies23,31,33 that analyzed patients undergoing TAVI;
the results did not differ from the previous ones (OR, 0.51;
95% CI: 0.32, 0.84; P=0.006; I2=63%; P=0.001).
Clinical and Demographic Variables
As showed in Figure S1, when major clinical and demographic
characteristics have been compared between BAV and TAV
patients, we found that BAV subjects were signiﬁcantly
younger than TAV (MD, 7.29; 95% CI: 11.17, 3.41;
P<0.001). In addition, BAV subjects were more frequently
males (72.7% vs 60.1%; OR, 1.61; 95% CI: 1.33, 1.94;
P<0.001) and exhibited a lower prevalence of hypertension
(43.0% vs 65.4%; OR, 0.58; 95% CI: 0.39, 0.87; P<0.001) and
diabetes (11.6% vs 16.3%; OR, 0.71; 95% CI: 0.54, 0.93;
P=0.01) than TAV. In contrast, no signiﬁcant differences were
found in prevalence of hyperlipidemia and smoking habit as
well as in mean BMI between BAV and TAV patients.
Interestingly, a metaregression analysis showed that
younger age and lower prevalence of diabetes were associ-
ated with lower prevalence of CAD (Z value: 3.03; P=0.002
and Z value: 3.10; P=0.002, respectively; Figure 5) and
CABG (Z value: 2.69; P=0.007 and Z value: 3.36; P=0.001,
respectively; Figure 6) documented in BAV patients as
compared to TAV patients.
Sensitivity Analysis
Given the statistically signiﬁcant difference in distribution of
age, sex, hypertension, and diabetes between BAV and TAV
patients, all the analyses have been repeated after including
only studies enrolling patients comparable for all these
variables.30,33,40–42 Interestingly, the difference in prevalence
of CAD (OR, 0.65; 95%CI, 0.33, 1.26; P=0.20) andmortality rate
(OR, 1.77; 95% CI, 0.81, 3.87; P=0.15) were no longer
signiﬁcant. None of the 5 studies enrolling patients comparable
for age, sex, hypertension, and diabetes provided information
about concomitant CABG in BAV and TAV subjects. Thus, the
sensitivity analysis was not performed for this outcome. When
stratifying results according to the study design (retrospective
or prospective), we found that the difference in CAD, concomi-
tant CABG, and postoperative mortality between BAV and TAV
patients were consistently conﬁrmed only by retrospective
studies. Interestingly, all the differences between the 2 groups
were no longer signiﬁcant in prospective studies (Table 2).
Figure 2. Prevalence of coronary artery disease in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
***References 12, 19–21, 23, 25, 27–31, 33, 34, 36, 37, 39.
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Publication Bias
Because it is recognized that publication bias can affect
results of meta-analyses, we attempted to assess this
potential bias using funnel plot visual analysis (Figure S2).
Visual inspection of funnel plots of effect size versus SE for
studies evaluating CAD, CABG, and mortality in BAV and in
TAV patients suggested a symmetric distribution of studies
around the effect size, and the Egger test conﬁrmed the lack
of publication bias for all these outcomes (CAD, P=0.868;
CABG, P=0.914; mortality, P=0.403).
Discussion
This meta-analysis, which includes more than 7500 patients
undergoing aortic valve surgery, shows, in agreement with
Figure 4. Post-operative mortality in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Figure 3. Prevalence of coronary artery bypass grafting (CABG) in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
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previously published data, a lower prevalence of CAD (13.5%
vs 30.3%) and concomitant CABG (31% vs 45.7%) in BAV than
in TAV patients, accompanied by a marginally lower rate of
postoperative mortality (16.2% vs 18.8%). We also show that
BAV patients enrolled in the included studies were 7 years
younger, more often males (72.7% vs 60.1%), and exhibited
lower prevalence of hypertension (43.0% vs 65.4%) and
diabetes (11.6% vs 16.3%) compared to TAV patients
(Table S1).
Altogether, these data suggest that the lower cardiovas-
cular risk reported in BAV patients may be partly explained by
younger age and lower prevalence of some cardiovascular risk
factors in this clinical setting. Interestingly, a meta-regression
analysis conﬁrmed and extended this hypothesis, showing
that age and diabetes have a profound impact on the
difference in prevalence of CAD and CABG between BAV and
TAV patients. Moreover, when the analyses have been
repeated after including only those studies enrolling patients
matched for age, sex, hypertension, and diabetes, the
difference in prevalence of CAD and postoperative mortality
were no longer signiﬁcant between the 2 groups of patients.
Thus, patients with BAV typically develop aortic stenosis at a
younger age, usually before 65 years, compared to aortic
stenosis in patients with TAV, which more often develops after
age 70.44
Several studies analyzed prevalence of CAD in BAV and
TAV patients, concluding that this atherosclerotic disease is
uncommon in BAV, but is associated with TAV disease.9,24
However, recent developments suggest that “incidence of
CAD is high in patients with aortic valve degeneration, both in
those with tricuspid and bicuspid aortic valve.”13
Our analysis shows that although the incidence of all the
considered variables is lower in BAV compared to TAV
patients, a higher mean age and a higher prevalence of
hypertension and diabetes is found in the TAV group. The
potential impact of these confounding covariates should be
taken into account. Indeed, our sensitivity analysis shows that
once hypertension, sex, diabetes, and age are taken into
Figure 6. Meta-regression analysis. Effect of the difference in mean age (A) and in prevalence of diabetes (B) on prevalence of concomitant
coronary artery bypass grafting in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
Figure 5. Meta-regression analysis. Effect of the difference in mean age (A) and in prevalence of diabetes (B) on prevalence of coronary artery
disease in patients with bicuspid (BAV) and tricuspid aortic valve (TAV).
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account and only studies with patients comparable for these
variables are included, the differences in prevalence of CAD
between BAV and TAV patients is no longer signiﬁcant.
The ﬁnding that, in the TAV group, higher mean age and
increased prevalence of diabetes and hypertension are paral-
leled by a higher prevalence of CAD, concomitant CABG, and
postoperative mortality somehow supports the hypothesis that
the etiopathogenetic mechanism underling aortic valve degen-
eration is similar or complementary to coronary atherosclero-
sis. Indeed, recent evidence suggested that risk factors
responsible for pathogenesis of atherosclerosis are also related
to development of aortic calciﬁcation and stenosis.13,45,46
However, the reasons why many patients with CAD do not
develop aortic stenosis are still under debate. The major
explanation may reside in the anatomic variation in size and
diameter in normal tricuspid aortic valve47 and the genetic
predisposition to aortic calciﬁcation, such as lipoprotein(a)
expression levels encoded by the lipoprotein(a) gene.48
Another ﬁnding of our analysis is the marginally lower
postoperative mortality in BAV than in TAV patients. Evalu-
ating the risk of post operative mortality in BAV and TAV
patients, it is interesting to highlight that the only study19
providing an adjusted multivariate analysis showed that valve
morphology did not impact on mortality rate. Moreover,
similar ﬁndings have been conﬁrmed by Roberts et al.37,39 by
means of an unadjusted analysis. On the other hand, it is
noteworthy to stress that 4 studies20,27,28,32 consistently
highlighted that an increasing age was the main predictor of
postoperative mortality. Overall, these evidences conﬁrm and
extend our data suggesting that the difference in mean age
between BAV and TAV might, at least in part, explain the
difference in postoperative mortality documented in these 2
groups. Indeed, when we have analyzed only studies on
patients comparable for age, sex, hypertension, and diabetes,
the differences in postoperative mortality rate between BAV
and TAV patients were no longer signiﬁcant. In addition, after
stratifying results according to study design, we found that
differences between BAV and TAV patients were conﬁrmed
only by retrospective studies. Interestingly, all the differences
between the 2 groups were no longer signiﬁcant in prospec-
tive studies.
We recognize that our study has several potential limita-
tions. The studies included in our meta-analysis have different
inclusion and exclusion criteria with no clear deﬁnition of
CAD. In addition, most of the patients included in the analysis
had concomitant cardiovascular risk factors. Given that meta-
analysis is performed on aggregate data and some missing
information is present in each study, the multivariate
approach allowed for the adjustment for some (but not all)
potential confounders. Thus, although results of metaregres-
sion analyses were able to reﬁne analyses by assessing the
inﬂuence of most clinical and demographic variables on the
observed results, caution is necessary in overall results
interpretation. Moreover, heterogeneity among the studies
was generally signiﬁcant. Although it was not possible to
conclusively ascertain sources of heterogeneity, publication
bias did not affect results of our meta-analysis.
In conclusion, patients undergoing aortic valve replace-
ment might represent a potential bias. Patients undergoing
surgery are a subset of patients with BAV or TAV, and this
could inﬂuence the results. This might limit the reproducibility
of reported results. However, a large study49 reporting on
natural history of BAV and TAV patients not undergoing
surgery conﬁrmed the lack of difference in cardiovascular
mortality between the 2 groups. In addition, the studies
included analyzed not only aortic valve stenosis pathology, but
also aortic valve regurgitation. However, in the studies
analyzing both aortic valve pathologies,18,22,26,27,35 there are
no signiﬁcative differences between BAV and TAV groups.
A further potential confounder is represented by inclusion
of studies analyzing patients’ candidate for TAVI, who, besides
the older age, have a greater prevalence of comorbidities.
Table 2. Stratiﬁcation of the Studies: Retrospective and Prospective
No. of Studies OR (95% CI) Heterogeneity
CAD
Retrospective studies 8 0.37 (0.18, 0.76; P=0.007) I2: 84%; P<0.001
Prospective studies 7 0.30 (0.07, 1.32; P=0.11) I2: 87%; P<0.001
CABG
Retrospective studies 15 0.45 (0.35, 0.59; P<0.001) I2: 59%; P=0.002
Prospective studies 1 0.43 (0.02, 7.90; P=0.57) Not evaluable
Mortality
Retrospective studies 13 0.57 (0.34, 0.94; P=0.03) I2: 72%; P<0.001
Prospective studies 3 1.08 (0.41, 2.86; P=0.88) I2: 0%; P=0.95
CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; OR, odds ratio.
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However, a subanalysis excluding these 3 studies23,31,33
conﬁrmed all our ﬁndings.
In conclusion, the results of the meta-analysis here
presented shows that analysis of raw data clearly suggests
an association of aortic valve morphology with prevalence of
CAD, concomitant CABG, and postoperative mortality. Inter-
estingly, differences in age and diabetes have a profound
impact on prevalence of CAD and concomitant CABG between
BAV and TAV patients. Thus, based on our analysis, BAV
patients do not exhibit a lower risk of CAD compared to TAV
patients. However, further studies or patient-level meta-
analysis are needed to adjust results for potential con-
founders and deﬁnitely address this issue.
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Figure S1.Distribution of major clinical and demographic characteristics in patients 
with bicuspid (BAV) and tricuspid aortic valve (TAV).( A) sex, (B) age, (C) hypertension, 
(D) diabetes, (E) hyperlipedimia, (F) BMI and (F) smoking. 
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Figure S2.Funnel plots of effect size versus standard error for studies evaluating the 
prevalence of coronary artery disease (A), coronary artery bypass grafting (B), post-
operative mortality (C) in patients with bicuspid (BAV) and tricuspid aortic valve 
(TAV). 
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 Table S1. Summary table of meta-analysis results 
 
Outcome Number of studies Effect size 
CAD 15 studies 
1,163 BAV and 2,234 TAV OR: 0.33, 95%CI: 0.17, 0.65, p = 0.001 
CABG 16 studies  
1,782 BAV and 1,886 TAV OR: 0.45, 95%CI: 0.35, 0.59, p < 0.001 
Mortality 16 studies 
1067 BAV and 2399 TAV OR: 0.62, 95%CI: 0.40, 0.97, p = 0.04 
Age 19 studies 
1489 BAV and 2530 TAV MD: -7.29, 95%CI: -11.17, -3.41, p < 0.001 
Male gender 23 studies 
1896 BAV and 3670 TAV OR: 1.61, 95%CI: 1.33, 1.94, p < 0.001 
Hypertension  20 studies 
1585 BAV and 3323 TAV OR: 0.58, 95%CI: 0.39, 0.87, p < 0.001 
Diabetes  20 studies 
1585 BAV and 3323 TAV OR: 0.71, 95%CI: 0.54, 0.93, p = 0.01 
Hyperlipidemia 11 studies 
880 BAV and 1095 TAV OR: 0.65, 95%CI: 0.28, 1.51, p = 0.32 
BMI 5 studies 
159 BAV and 705 TAV MD: 0.64, 95%CI: -0.69, 1.97, p = 0.34 
Smoking habit 9 studies 
523 BAV and 973 TAV OR: 1.52, 95%CI: 0.90, 2.59, p = 0.12 
CAD: coronary artery disease; CABG: Coronary artery bypass grafting; BMI: body mass 
index; BAV: bicuspid aortic valve; TAV; tricuspid aortic valve; OR: odds ratio; MD: mean 
difference; 95%CI: 95% confidence intervals  
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